Patents by Inventor Diana Strehl

Diana Strehl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions comprising nebivolol
    Patent number: 11576893
    Abstract: The present invention relates to pharmaceutical compositions comprising the selective beta 1 (B1)-receptor blocker nebivolol and/or a pharmaceutically acceptable salt thereof and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention is useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: February 14, 2023
    Assignee: NOVALIQ GMBH
    Inventors: Frank Löscher, Kirsten Eickhoff, Diana Strehl
  • OPHTHALMIC COMPOSITIONS COMPRISING TAFLUPROST FOR THE TREATMENT OF GLAUCOMA
    Publication number: 20210228595
    Abstract: The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein the composition comprises tafluprost and a semifluorinated alkane.
    Type: Application
    Filed: April 24, 2019
    Publication date: July 29, 2021
    Inventors: Frank LÖSCHER, Diana STREHL, Kirsten EICKHOFF
  • PHARMACEUTICAL COMPOSITIONS COMPRISING TIMOLOL
    Publication number: 20210121471
    Abstract: The present invention relates to pharmaceutical composition comprising the beta 1(?1)-receptor blocker timolol and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention may be useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.
    Type: Application
    Filed: March 25, 2019
    Publication date: April 29, 2021
    Inventors: Frank LÖSCHER, Sonja KRÖSSER, Diana STREHL, Bernhard HAUPTMEIER, Kirsten EICKHOFF
  • PHARMACEUTICAL COMPOSITIONS COMPRISING NEBIVOLOL
    Publication number: 20210106558
    Abstract: The present invention relates to pharmaceutical compositions comprising the selective beta 1 (B1)-receptor blocker nebivolol and/or a pharmaceutically acceptable salt thereof and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention is useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.
    Type: Application
    Filed: March 1, 2019
    Publication date: April 15, 2021
    Inventors: Frank LÖSCHER, Kirsten EICKHOFF, Diana STREHL
  • PHARMACEUTICAL COMPOSITION CONTAINING A TRYPTOPHAN DERIVATIVE
    Publication number: 20180118682
    Abstract: Pharmaceutical compositions containing a compound of formula (I) wherein the radicals denote e.g.: R1 is hydrogen or C1-C8-alkyl; R2 is hydrogen or C1-C8-alkyl; R3 is hydrogen or C1-C8-alkyl; R4 is OH; R5 is hydrogen, and a pharmaceutically acceptable cyclodextrin derivative can be used for the preparation of ophthalmic formulations.
    Type: Application
    Filed: December 20, 2017
    Publication date: May 3, 2018
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventors: Bernard HAUPTMEIER, Kevin KIEHM, Patrick PLITT, Axel TARDT, Alda SZLAK-FREIER, Diana STREHL
  • PHARMACEUTICAL COMPOSITION CONTAINING A TRYPTOPHAN DERIVATIVE
    Publication number: 20130197053
    Abstract: Pharmaceutical compositions containing a compound of formula (I) wherein the radicals denote e.g.: R1 is hydrogen or C1-C8-alkyl; R2 is hydrogen or C1-C8-alkyl; R3 is hydrogen or C1-C8-alkyl; R4 is OH; R5 is hydrogen, and a pharmaceutically acceptable cyclodextrin derivative can be used for the preparation of ophthalmic formulations.
    Type: Application
    Filed: July 6, 2011
    Publication date: August 1, 2013
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Bernard Hauptmeier, Kevin Kiehm, Patrick Plitt, Axel Tardt, Alda Szlak-Freier, Diana Strehl